An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche5 enrolled

Overview

This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient as per routine clinical practice of the Investigator (maximum of 52 weeks, until disease progression /unacceptable toxicity or withdrawal of consent) and/or based on the local label.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Renal Cell Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Advanced and/or metastatic renal cell carcinoma * Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label * At least one measurable and non-measurable lesion according to RECIST criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate bone marrow, renal and liver function Exclusion Criteria: * Contraindications to Avastin and/or interferon alpha-2a as per local label

Locations (2)

Unnamed facility

Aurangabad, India

Outcomes

Primary Outcomes

Safety: Incidence of adverse events

Time frame: approximately 4 years

Secondary Outcomes

Progression-free survival: time from first drug administration to documented disease progression or death of any cause

Time frame: approximately 4 years

Overall response rate: complete response or partial response according to RECIST criteria

Time frame: approximately 4 years

Overall survival

Time frame: approximately 4 years